RT Journal Article
SR Electronic
T1 IgA autoantibodies target pulmonary surfactant in patients with severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.02.21250940
DO 10.1101/2021.02.02.21250940
A1 Sinnberg, Tobias
A1 Lichtensteiger, Christa
A1 Ali, Omar Hasan
A1 Pop, Oltin T.
A1 Gilardi, Mara
A1 Risch, Lorenz
A1 Bomze, David
A1 Kohler, Philipp
A1 Vernazza, Pietro
A1 Albrich, Werner C.
A1 Kahlert, Christian R.
A1 Brugger, Silvio D.
A1 Abdou, Marie-Therese
A1 Zinner, Carl
A1 Tzankov, Alexandar
A1 Röcken, Martin
A1 Kern, Lukas
A1 Brutsche, Martin H.
A1 Kalbacher, Hubert
A1 Velic, Ana
A1 Maček, Boris
A1 Penninger, Josef M.
A1 Matter, Matthias S.
A1 Flatz, Lukas
YR 2021
UL http://medrxiv.org/content/early/2021/02/05/2021.02.02.21250940.abstract
AB Complications affecting the lung are hallmarks of severe coronavirus disease 2019 (COVID-19). While there is evidence for autoimmunity in severe COVID-19, the exact mechanisms remain unknown. Here, we established a prospective observational cohort to study lung specific autoantibodies (auto-Abs). Incubation of plasma from severe COVID-19 patients with healthy human lung tissue revealed the presence of IgA antibodies binding to surfactant-producing pneumocytes. Enzyme-linked immunosorbent assays (ELISA) and protein pull-downs using porcine surfactant confirmed the presence of auto-Abs binding to surfactant proteins in severe COVID-19 patients. Mass spectrometry and ELISAs with recombinant proteins identified IgA auto-Abs that target human surfactant proteins B and C. In line with these findings, lungs of deceased COVID-19 patients showed reduced pulmonary surfactant. Our data suggest that IgA-driven autoimmunity against surfactant may result in disease progression of COVID-19.Competing Interest StatementJ.M.P. is founder and shareholder of Apeiron (Vienna, Austria), developing soluble ACE2 as a COVID-19 therapy. J.M.P. has no direct competing interest relating to the paper or data presented in the paper. All other authors have no competing interests to declare.Funding StatementThis research was supported by grants from the Swiss National Science Foundation (PP00P3_157448 to L.F., P400PM_194473 to O.H.A.), the Research Fund of the Kantonsspital St. Gallen (20/20 to L.F.), and the Promedica Foundation (1449/M to S.D.B.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics committee of Eastern Switzerland (study ID 2020-01006) and Ethics committee of Northern and Central Switzerland (study ID 2020-00969).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, L.F., upon reasonable request.